Indalo Therapeutics is a biopharmaceutical company discovering and developing novel integrin antagonists for patients suffering from serious fibrotic diseases, such as nonalcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF). The Company has developed a drug candidate, IDL-2965, which is an oral, selective, RGD-binding integrin antagonist that inhibits the activation of TGF-β (a fibrogenic growth factor) as well as the ability of the stiff extracellular matrix to promote fibroblast migration and survival.
|HQ||Cambridge, MA, US||Map|
|Employees (est.) (Jun 2021)||5|
Indalo Therapeutics total Funding
Indalo Therapeutics latest funding size
Time since last funding
|4 years ago|
Indalo Therapeutics investors
|Atlas Venture, F-Prime Capital Partners, Argonautic Ventures|
Indalo Therapeutics has 67 Twitter Followers. The number of followers has increased 8.1% month over month and increased 9.4% quarter over quarter
When was Indalo Therapeutics founded?
Indalo Therapeutics was founded in 2014.
Who are Indalo Therapeutics key executives?
Indalo Therapeutics's key executives are Scott D. Seiwert, Peter Barrett and Williamson Z. Bradford.
How many employees does Indalo Therapeutics have?
Indalo Therapeutics has 5 employees.
Who are Indalo Therapeutics competitors?
Competitors of Indalo Therapeutics include Arch Oncology, Igyxos and Imara.
Where is Indalo Therapeutics headquarters?
Indalo Therapeutics headquarters is located at 400 Technology Square, 400 Technology Square 10th floor, Cambridge.
Where are Indalo Therapeutics offices?
Indalo Therapeutics has an office in Cambridge.
How many offices does Indalo Therapeutics have?
Indalo Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies